Discovery of a potent, selective and orally bioavailable SOS1 inhibitor, RMC-023, an in vivo tool compound that blocks RAS activation via disruption of the RAS-SOS1 interaction

A. Buckl, E. Quintana, G.J. Lee, N. Shifrin, M. Zhong, L. S. Garrenton, D. C. Montgomery, C. Stahlhut, F. Zhao, D. M. Whalen, S. K. Thompson, A. Tambo-ong, M. Gliedt, J. E. Knox, J. J. Cregg, N. Aay, J. Choi, B. Nguyen, R. Zhao, A. Tripathi, M. Saldajeno-Concar, A. Tomlinson, A. Marquez, D. Hsieh, L. McDowell, E.S. Koltun, A. Bermingham, D. Wildes, M. Singh, Z. Wang, R. Hansen, J.A.M. Smith, A. L. Gill

American Association for Cancer Research Annual Meeting 2021, Virtual Meeting I; April 10-15, 2021. Poster 1273.